VRTX: third_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/989e0ddf-974b-4d03-a947-7c0dbe59c9ed/","filing_uuid":"989e0ddf-974b-4d03-a947-7c0dbe59c9ed","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/989e0ddf-974b-4d03-a947-7c0dbe59c9ed/print/","filing_document_content_type":"text/html","income":null,"expenses":"1100000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Samantha Ventimiglia","dt_posted":"2026-10-19T15:22:46-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"50 Northern Avenue","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Boston","registrant_state":"MA","registrant_zip":"02210","registrant":{"id":40027242,"url":"https://lda.gov/api/v1/registrants/40027242/","house_registrant_id":39888,"name":"VERTEX PHARMACEUTICALS INCORPORATED","description":"Global biotechnology company","address_1":"50 Northern Avenue","address_2":null,"address_3":null,"address_4":null,"city":"Boston","state":"MA","state_display":"Massachusetts","zip":"02210","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SAMANTHA VENTIMIGLIA","contact_telephone":"+1 202-264-3511","dt_updated":"2026-07-29T12:53:27.346758-04:00"},"client":{"id":188223,"url":"https://lda.gov/api/v1/clients/188223/","client_id":48,"name":"VERTEX PHARMACEUTICALS INCORPORATED","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-02-14"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143272,"prefix":null,"prefix_display":null,"first_name":"SWARNA","nickname":null,"middle_name":null,"last_name":"VALLURUPALLI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145288,"prefix":"ms","prefix_display":"MS.","first_name":"HANNAH","nickname":null,"middle_name":"BETH","last_name":"CORNWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153466,"prefix":null,"prefix_display":null,"first_name":"KYLE","nickname":null,"middle_name":null,"last_name":"HILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146733,"prefix":"ms","prefix_display":"MS.","first_name":"KRISTIN","nickname":"SEUM","middle_name":null,"last_name":"RICHTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145288,"prefix":"ms","prefix_display":"MS.","first_name":"HANNAH","nickname":null,"middle_name":"BETH","last_name":"CORNWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143272,"prefix":null,"prefix_display":null,"first_name":"SWARNA","nickname":null,"middle_name":null,"last_name":"VALLURUPALLI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153466,"prefix":null,"prefix_display":null,"first_name":"KYLE","nickname":null,"middle_name":null,"last_name":"HILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146733,"prefix":"ms","prefix_display":"MS.","first_name":"KRISTIN","nickname":"SEUM","middle_name":null,"last_name":"RICHTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Issues related to the Defense Health Agency and service member access to non-opioid alternatives, including reinstating the DHA Benefits Advisory Panel and the structured formulary management process.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145288,"prefix":"ms","prefix_display":"MS.","first_name":"HANNAH","nickname":null,"middle_name":"BETH","last_name":"CORNWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143272,"prefix":null,"prefix_display":null,"first_name":"SWARNA","nickname":null,"middle_name":null,"last_name":"VALLURUPALLI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to Sec. 232 pharmaceutical tariffs, onshoring active pharmaceutical ingredients (API), and supply chain disruptions for products related to the opioid public health emergency.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145288,"prefix":"ms","prefix_display":"MS.","first_name":"HANNAH","nickname":null,"middle_name":"BETH","last_name":"CORNWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146733,"prefix":"ms","prefix_display":"MS.","first_name":"KRISTIN","nickname":"SEUM","middle_name":null,"last_name":"RICHTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143272,"prefix":null,"prefix_display":null,"first_name":"SWARNA","nickname":null,"middle_name":null,"last_name":"VALLURUPALLI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145288,"prefix":"ms","prefix_display":"MS.","first_name":"HANNAH","nickname":null,"middle_name":"BETH","last_name":"CORNWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153466,"prefix":null,"prefix_display":null,"first_name":"KYLE","nickname":null,"middle_name":null,"last_name":"HILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146733,"prefix":"ms","prefix_display":"MS.","first_name":"KRISTIN","nickname":"SEUM","middle_name":null,"last_name":"RICHTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":73549,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":"O","last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143272,"prefix":null,"prefix_display":null,"first_name":"SWARNA","nickname":null,"middle_name":null,"last_name":"VALLURUPALLI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145288,"prefix":"ms","prefix_display":"MS.","first_name":"HANNAH","nickname":null,"middle_name":"BETH","last_name":"CORNWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153466,"prefix":null,"prefix_display":null,"first_name":"KYLE","nickname":null,"middle_name":null,"last_name":"HILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146733,"prefix":"ms","prefix_display":"MS.","first_name":"KRISTIN","nickname":"SEUM","middle_name":null,"last_name":"RICHTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":10,"name":"Vice President of the U.S."},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143272,"prefix":null,"prefix_display":null,"first_name":"SWARNA","nickname":null,"middle_name":null,"last_name":"VALLURUPALLI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}